Open AccessEsophageal Cancer: New Insights into a Heterogenous Disease
Author(s) -
Sebastian Krug,
Patrick Michl
Publication year - 2017
Publication title -
digestion
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.882
H-Index - 75
eISSN - 1421-9867
pISSN - 0012-2823
DOI - 10.1159/000464130
Subject(s) - medicine , neoadjuvant therapy , esophageal cancer , oncology , perioperative , malignancy , tolerability , cancer , chemoradiotherapy , chemotherapy , clinical trial , multimodal therapy , surgery , adverse effect , breast cancer
Esophageal cancer represents a heterogeneous malignancy mostly diagnosed in advanced stages. Worldwide, squamous cell carcinomas (SCCs) continue to be the most prevalent subtype; however, in the Western countries, the incidence of adenocarcinomas is increasing and will exceed that of SCC in the near future. During the last decade, several landmark trials contributed to a better understanding of the disease and emphasized the importance of multimodal treatment protocols.